Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.
Alexandra LitvinchukTien-Phat V HuynhYang ShiRosemary J JacksonMary B FinnMelissa ManisCaroline M FrancisAinsley C TranPatrick M SullivanJason D UlrichBradley T HymanTracy ColeDavid M HoltzmanPublished in: Annals of neurology (2021)
We conclude that reducing ApoE4 levels should be explored further as a therapeutic approach for APOE4 carriers with tauopathy including Alzheimer's disease. ANN NEUROL 2021;89:952-966.